Latest Trials Latest NewsFAQ

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cellular Therapy With Cord Blood Cells

Phase 2

Completed

Conditions: Multiple Myeloma
Leukemia
Lymphoma

Interventions: Drug: Fludarabine
Drug: Melphalan
Procedure: Umbilical Cord Blood
Drug: Rituximab
Other: Peripheral Blood Stem Cell Infusion

First Posted Date: 2007-01-29

Last Posted Date: 2012-05-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00427557

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma
Lymphoma

Interventions: Drug: Busulfan
Drug: Melphalan

First Posted Date: 2007-01-29

Last Posted Date: 2012-01-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 168

Registration Number: NCT00427765

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Not Applicable

Completed

Conditions: Aplastic Anemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Antithymocyte Globulin

First Posted Date: 2007-01-29

Last Posted Date: 2011-10-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT00427336

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Etoposide
Radiation: Total Body Irradiation
Drug: Rituximab

First Posted Date: 2007-01-29

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00427791

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Proton Therapy and Bevacizumab for Primary Liver Tumors

Phase 1

Terminated

Conditions: Liver Cancer
Hepatocellular Carcinoma
Cholangiocarcinoma

Interventions: Drug: Bevacizumab
Radiation: Proton Radiation Therapy

First Posted Date: 2007-01-25

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00426829

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Voraxaze for Delayed Methotrexate Clearance

Phase 1

Terminated

Conditions: Hematologic Malignancy
Solid Tumor

Interventions: Drug: Placebo
Drug: Voraxaze (Glucarpidase)

First Posted Date: 2007-01-19

Last Posted Date: 2012-12-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00424645

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Parenteral Hydration in Advanced Cancer Patients

Not Applicable

Completed

Conditions: Dehydration
Advanced Cancer

Interventions: Drug: Saline

First Posted Date: 2007-01-18

Last Posted Date: 2024-03-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 262

Registration Number: NCT00423722

Locations: 🇺🇸
Odyssey Healthcare of Conroe, Conroe, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Vitas Healthcare, Houston, Texas, United States

and more 2 locations

Allogeneic Blood Stem Cell Transplantation

Not Applicable

Completed

Conditions: Hodgkin's Disease

First Posted Date: 2007-01-18

Last Posted Date: 2012-01-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00423709

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Interactive Voice Response (IVR) Symptom Assessment in Non-Small Cell Lung Cancer (NSCLC) Patients

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Behavioral: Questionnaire
Behavioral: Interactive Voice Response Telephone System
Behavioral: IVR Plus Triage

First Posted Date: 2007-01-18

Last Posted Date: 2011-12-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 84

Registration Number: NCT00423436

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Methylphenidate and a Nursing Telephone Intervention for Fatigue

Phase 2

Completed

Conditions: Advanced Cancer
Fatigue

Interventions: Drug: Methylphenidate
Drug: Placebo
Behavioral: Non NTI
Behavioral: Nursing Telephone Intervention

First Posted Date: 2007-01-18

Last Posted Date: 2023-06-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 197

Registration Number: NCT00424099

Locations: 🇺🇸
Lyndon Baines Johnson (LBJ) Hospital, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy